Esperion Therapeutics Inc (ESPR)

概要ニュース株価時系列オプションチェーン Financials なぜESPRが下落しているのか？ディスカッション予測株式分割

なぜEsperion Therapeutics Inc（ESPR）の株価が下がっていますか？

2024-09-16 の取引セッション中に、Esperion Therapeutics Inc (ESPR) 株の 7.85% 下落を確認しました。これは通常のボラティリティやさまざまな内部および外部要因に起因する可能性がありますが、当社では状況を積極的に監視しており、できるだけ早くタイムリーな最新情報を提供することに注意してください。

2024-01-03:

Esperion Therapeutics Inc. (ESPR) stock dropped by 21.23% due to the announcement of a $125 million amendment to the collaboration between Esperion Therapeutics and Daiichi Sankyo Europe GmbH (DSE), the European headquarters of Daiichi Sankyo Co., Ltd., a Japanese pharmaceutical company.

Collaboration Amendment Details: The amendment involved DSE paying Esperion $100 million in anticipation of a regulatory approval by the European Medicines Agency (EMA) and an additional $25 million payment after EMA's decision. The parties also resolved a legal action. Additionally, the agreement included a transition of manufacturing responsibilities to DSE, potential collaboration expansion for a new product, and DSE leading regulatory communications with EMA.
Impact on Stock Price: The stock's significant decline likely resulted from investor reactions to the financial and operational changes arising from the collaboration amendment. The resolution and adjustments could have implications for Esperion Therapeutics' future business prospects, influencing the stock's performance.